Wave Life Sciences' Obesity Drug Shows Promising Fat Loss Without Muscle Decline

Wave Life Sciences' WVE-007 demonstrates 9.4% visceral fat reduction with muscle preservation in Phase 1 trial, earning positive analyst ratings and buy recommendations.